为“老守卫”配备“新的双重靶向武器”。

Arming "old guards" with "new dual-targeting weapons".

机构信息

Stem Cell Transplantation Program and Cellular Therapy Program, Division of Oncology/Hematology, Department of Medicine, University of Virginia Cancer Center, Charlottesville, VA, USA.

Laboratory of Novel Biologics, Department of Biochemistry and Molecular Genetics, University of Virginia Cancer Center, Charlottesville, VA, USA.

出版信息

Cancer Cell. 2021 May 10;39(5):604-606. doi: 10.1016/j.ccell.2021.04.010.

DOI:10.1016/j.ccell.2021.04.010

PMID:33974858

Abstract

The long-held paradigm that tumor suppressors are un-targetable in cancer therapy is challenged by a study published in Science. This recent work elegantly describes and characterizes a p53 mutant peptide-selective TCR-mimic antibody and its co-targeting T cell-activating bispecific antibody to eliminate neoantigen-expressing tumors.

摘要

长期以来，肿瘤抑制因子在癌症治疗中不可靶向的观点受到了《科学》杂志上一项研究的挑战。这项最近的工作巧妙地描述和表征了一种 p53 突变肽选择性 TCR 模拟抗体及其共靶向 T 细胞激活双特异性抗体，以消除表达新抗原的肿瘤。